SCHEMBL619940

SCHEMBL619940

NCCN[C@H](CS)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.56
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
PTGS2 P35354 1/20 0.47
THPO P40225 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ACE P12821 1/20 0.42
CPB2 Q96IY4 9/20 0.41
FOLH1 Q04609 1/20 0.40
PTGS1 P23219 1/20 0.39
SLC7A11 Q9UPY5 1/20 0.39
CPB1 P15086 1/20 0.39
GABRR1 P24046 2/20 0.37
ENPEP Q07075 2/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL307700 1.00 GGT1 (0.56) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL94249 1.00 GGT1 (0.56) GGT1KDM4EMAPTTHRBALOX15
Hydrochloric Acid SCHEMBL1574244 0.98 GGT1 (0.55) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL5965362 0.88 CPB2 (0.47) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL4996803 0.88 CPB2 (0.47) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL900178 0.86 KDM4E (0.54) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL900182 0.86 KDM4E (0.54) GGT1KDM4EMAPTTHRBALOX15
SCHEMBL17378062 0.86 KDM4E (0.54) GGT1KDM4EMAPTTHRBALOX15
Hydrochloric Acid SCHEMBL16993797 0.84 KDM4E (0.52) GGT1KDM4EMAPTTHRBALOX15
Lysine SCHEMBL9118672 0.83 GSR (0.61) GGT1CPB2FOLH1PTGS1SLC7A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190016766-A1 Use of improved modulators of complement function as cancer therapeutics BENJAMIN DANIEL E (US) 2019-01-17 US claimed
US-20180369328-A1 Modulators of Complement Function FRITZINGER DAVID C (US) 2018-12-27 US claimed
US-20090203585-A1 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. 2009-08-13 US claimed
US-7525013-B2 Soybean selection system based on AEC-resistance UNITED SOYBEAN BOARD (US) 2009-04-28 US claimed
WO-2007130743-A2 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS ARRAY BIOPHARMA, INC. (US) 2007-11-15 WO claimed
US-20060117413-A1 Soybean selection system based on aec-resistance UNITED SOYBEAN BOARD (US) 2006-06-01 US claimed
US-20060009468-A1 Method for treatment of cancer CROOKS PETER A 2006-01-12 US claimed
WO-2005017108-A2 SOYBEAN SELECTION SYSTEM BASED ON AEC-RESISTANCE UNITED SOYBEAN BOARD (US) 2005-02-24 WO claimed
US-5859295-A Canavanine analogs and their use as chemotherapeutic agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1999-01-12 US claimed
US-5552440-A Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1996-09-03 US claimed
EP-0422187-B1 PRODUCTION OF AMINO ACIDS BY METHYLOTROPHIC BACILLUS UNIV MINNESOTA (US) 1995-09-20 EP claimed
EP-0336387-B1 PROCESS FOR PRODUCING L-ARGININE KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1993-08-04 EP claimed
US-5034319-A Culture of corynebacterium in a medium of cysteine KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-07-23 US claimed
EP-0422187-A1 PRODUCTION OF AMINO ACIDS BY METHYLOTROPHIC BACILLUS. UNIV MINNESOTA (US) 1991-04-17 EP claimed
WO-1990012105-A2 PRODUCTION OF AMINO ACIDS BY METHYLOTROPHIC BACILLUS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1990-10-18 WO claimed
EP-0336387-A2 Process for producing L-arginine KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1989-10-11 EP claimed
US-20250171500-A1 CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS CALDER BIOSCIENCES INC (US) 2025-05-29 US disclosed
US-20250092094-A1 CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS CALDER BIOSCIENCES INC (US) 2025-03-20 US disclosed
US-4368266-A MUTANTS OF BREVIBACTERIUM OR CORYNEBACTERIUM REQUIRING ACETIC ACID FOR GROWTH AJINOMOTO COMPANY INCORPORATED (JP) 1983-01-11 US disclosed
US-4347317-A BREVIBACTERIUM OR CORYNEBACTERIUM MUTANTS AJINOMOTO COMPANY, INCORPORATED (JP) 1982-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203585-A1 CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS CAPRIN1, NISCH, RPIA GGT1 2038/4885KDM4E 2843/4885MAPT 2831/4885
US-20060009468-A1 Method for treatment of cancer TOP2A, TOP2B, TOP1 GGT1 362/4885KDM4E 2110/4885MAPT 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.